Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Akihiro Funakoshi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0383-8901; OpenAlex author ID A5044537449, A5055281656, A5111847114. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers

Papers 10

  1. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  2. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  3. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.12.362↗
  4. [Various cancers related type 2 diabetes mellitus: Pancreatic cancer]. Co-author PMID 27266128↗
  5. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  6. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  7. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗
  8. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗
  9. Giardiasis in the pancreas accompanied by pancreatic cancer. Last author DOI 10.1097/mpa.0b013e3181f6a1b9↗
  10. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinichi Ohkawa · 8 shared papers, 2011–2017 · strength 0.27
  2. Takuji Okusaka · 8 shared papers, 2011–2017 · strength 0.27
  3. Junji Furuse · 7 shared papers, 2011–2017 · strength 0.24
  4. Narikazu Boku · 5 shared papers, 2011–2017 · strength 0.18
  5. Kenji Yamao · 5 shared papers, 2011–2017 · strength 0.18
  6. Tatsuya Ioka · 5 shared papers, 2011–2017 · strength 0.17
  7. Taketo Yamaguchi · 4 shared papers, 2013–2017 · strength 0.17
  8. Shoji Nakamori · 4 shared papers, 2011–2017 · strength 0.13
  9. Takashi Hatori · 3 shared papers, 2013–2017 · strength 0.13
  10. Shinichi Egawa · 3 shared papers, 2013–2017 · strength 0.13
  11. Ann‐Lii Cheng · 3 shared papers, 2013–2017 · strength 0.13
  12. Yasuo Ohashi · 3 shared papers, 2013–2017 · strength 0.13
  13. Masao Tanaka · 3 shared papers, 2013–2017 · strength 0.13
  14. Yasuo Hamamoto · 2 shared papers, 2015–2017 · strength 0.08
  15. Atsushi Satō · 2 shared papers, 2013–2017 · strength 0.08
  16. Hideki Ueno · 2 shared papers, 2013–2017 · strength 0.08
  17. Hiroshi Ishii · 2 shared papers, 2015–2016 · strength 0.07
  18. Akira Fukutomi · 2 shared papers, 2013–2015 · strength 0.06
  19. Hiroaki Yanagimoto · 2 shared papers, 2013–2015 · strength 0.06
  20. Hideo Baba · 2 shared papers, 2013–2015 · strength 0.06
  21. Masafumi Ikeda · 2 shared papers, 2013–2015 · strength 0.06
  22. Masayuki Sho · 2 shared papers, 2013–2015 · strength 0.06
  23. Yasuhiro Hagiwara · 1 shared paper, 2017 · strength 0.05
  24. Hirofumi Fujii · 1 shared paper, 2017 · strength 0.05
  25. Hideki Ueno · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.